Literature DB >> 28794865

Recent advances in acute promyelocytic leukaemia.

Chin-Hin Ng1, Wee-Joo Chng1.   

Abstract

Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the PML-RARA fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.

Entities:  

Keywords:  PML; RARA; leukemia

Year:  2017        PMID: 28794865      PMCID: PMC5538034          DOI: 10.12688/f1000research.10736.1

Source DB:  PubMed          Journal:  F1000Res        ISSN: 2046-1402


  70 in total

1.  Arsenic trioxide therapy in relapsed or refractory Japanese patients with acute promyelocytic leukemia: updated outcomes of the phase II study and postremission therapies.

Authors:  Kazuyuki Shigeno; Kensuke Naito; Naohi Sahara; Miki Kobayashi; Satoki Nakamura; Sinya Fujisawa; Kaori Shinjo; Akihiro Takeshita; Ryuzo Ohno; Kazunori Ohnishi
Journal:  Int J Hematol       Date:  2005-10       Impact factor: 2.490

2.  Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.

Authors:  Antonio R Lucena-Araujo; Haesook T Kim; Rafael H Jacomo; Raul A Melo; Rosane Bittencourt; Ricardo Pasquini; Katia Pagnano; Evandro M Fagundes; Maria de Lourdes Chauffaille; Carlos S Chiattone; Ana Silvia Lima; Guillermo Ruiz-Argüelles; Maria Soledad Undurraga; Lem Martinez; Hau C Kwaan; Robert Gallagher; Charlotte M Niemeyer; Stanley L Schrier; Martin S Tallman; David Grimwade; Arnold Ganser; Nancy Berliner; Raul C Ribeiro; Francesco Lo-Coco; Bob Löwenberg; Miguel A Sanz; Eduardo M Rego
Journal:  Ann Hematol       Date:  2014-07-02       Impact factor: 3.673

3.  Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients.

Authors:  C Niu; H Yan; T Yu; H P Sun; J X Liu; X S Li; W Wu; F Q Zhang; Y Chen; L Zhou; J M Li; X Y Zeng; R R Yang; M M Yuan; M Y Ren; F Y Gu; Q Cao; B W Gu; X Y Su; G Q Chen; S M Xiong; T D Zhang; S Waxman; Z Y Wang; Z Chen; J Hu; Z X Shen; S J Chen
Journal:  Blood       Date:  1999-11-15       Impact factor: 22.113

4.  BCOR as a novel fusion partner of retinoic acid receptor alpha in a t(X;17)(p11;q12) variant of acute promyelocytic leukemia.

Authors:  Yukiya Yamamoto; Sachiko Tsuzuki; Motohiro Tsuzuki; Kousuke Handa; Yoko Inaguma; Nobuhiko Emi
Journal:  Blood       Date:  2010-08-31       Impact factor: 22.113

5.  Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy.

Authors:  Wing-Yan Au; Sidney Tam; Bonnie M Fong; Yok-Lam Kwong
Journal:  Blood       Date:  2008-08-14       Impact factor: 22.113

6.  The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion.

Authors:  R L Redner; E A Rush; S Faas; W A Rudert; S J Corey
Journal:  Blood       Date:  1996-02-01       Impact factor: 22.113

Review 7.  Early mortality and the retinoic acid syndrome in acute promyelocytic leukemia: impact of leukocytosis, low-dose chemotherapy, PMN/RAR-alpha isoform, and CD13 expression in patients treated with all-trans retinoic acid.

Authors:  L Vahdat; P Maslak; W H Miller; A Eardley; G Heller; D A Scheinberg; R P Warrell
Journal:  Blood       Date:  1994-12-01       Impact factor: 22.113

8.  Acute promyelocytic leukemia. Therapy results and prognostic factors.

Authors:  M A Sanz; I Jarque; G Martín; I Lorenzo; J Martínez; J Rafecas; E Pastor; M J Sayas; G Sanz; F Gomis
Journal:  Cancer       Date:  1988-01-01       Impact factor: 6.860

Review 9.  Thrombosis in acute promyelocytic leukemia.

Authors:  Armin Rashidi; Marc L Silverberg; Paul R Conkling; Stephen I Fisher
Journal:  Thromb Res       Date:  2012-12-23       Impact factor: 3.944

10.  Long-term prognosis of childhood acute promyelocytic leukaemia with arsenic trioxide administration in induction and consolidation chemotherapy phases: a single-centre experience.

Authors:  Yifei Cheng; Leping Zhang; Jun Wu; Aidong Lu; Bin Wang; Guilan Liu
Journal:  Eur J Haematol       Date:  2013-09-17       Impact factor: 2.997

View more
  5 in total

1.  Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country.

Authors:  Warkha Thakur; Nida Anwar; Naveena Fatima; Aisha Jamal; Quratul Ain Rizvi; Munira Borhany
Journal:  Cureus       Date:  2022-06-17

Review 2.  The SUMO Pathway in Hematomalignancies and Their Response to Therapies.

Authors:  Mathias Boulanger; Rosa Paolillo; Marc Piechaczyk; Guillaume Bossis
Journal:  Int J Mol Sci       Date:  2019-08-09       Impact factor: 5.923

3.  Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.

Authors:  Pierre Gâtel; Frédérique Brockly; Christelle Reynes; Manuela Pastore; Yosr Hicheri; Guillaume Cartron; Marc Piechaczyk; Guillaume Bossis
Journal:  Life Sci Alliance       Date:  2020-04-17

4.  Overall survival of adult acute myeloid leukemia based on cytogenetic and molecular abnormalities during 5 years in a single center study.

Authors:  Enaam Alsobhi; Fayssal Farahat; Mostafa Daghistani; Khadeja Awad; Omar Al-Zahran; Afaf Al-Saiari; Fai Koshak
Journal:  Saudi Med J       Date:  2019-11       Impact factor: 1.484

5.  Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.

Authors:  Michele May-Sien Tana; Arielle Klepper; Amy Lyden; Angela Oliveira Pisco; Maira Phelps; Breann McGee; Kelsey Green; Sandy Feng; Joseph DeRisi; Emily Dawn Crawford; Craig S Lammert
Journal:  PLoS One       Date:  2022-03-21       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.